Mereo BioPharma

Team Mereo in Germany were delighted to be invited to attend the DOIG https://lnkd.in/e6bH_d6U annual conference earlier this month. We enjoyed conversations with people with osteogenesis imperfecta (OI), caregivers and the DOIG Management Team. The sessions covered fascinating and far-ranging topics such as pain management in OI, positive psychology, the IMPACT Survey (www.impactsurvey.io) and scientific news. We also had an update from Fair4Rare (https://lnkd.in/ejh2-diH) on plans to establish a register with a core data set for OI to document the Burden of Disease. It was a privilege to participate in such a great event, particularly as it marked the 40th anniversary of DOIG. #osteogenesisimperfecta #OI #IMPACTSurveyoi

Orphanet Journal of Rare Diseases has published a paper seeking to estimate the epidemiology of osteogenesis imperfecta (OI) in Spain: ‘Current situation of osteogenesis imperfecta in Spain: results from a Delphi study’. https://lnkd.in/eZ7THnPR. As well as an estimate of the prevalence and incidence of OI in Spain, the results complement the available evidence of the burden of the disease, management, and unmet need. The study also highlights the priorities for improving the management of the condition:  availability of consensus documents and treatment guidelines, the establishment of multidisciplinary management throughout a person’s life, and the approval of the new therapies. Thank you to the clinician experts in OI who contributed real life experience and data from Spanish hospitals, supported the development of the study questionnaire and validated the final results. #osteogenesisimperfecta #OI

Team Mereo is heading to Austria for the 11th International Conference on Children’s Bone Health (ICCBH), run by the International Society for Children's Bone Health. We are looking forward to spending time with the community to continue to learn more about the latest developments in understanding paediatric bone health. This is the first year that Mereo has a medical booth and it will be great to meet fellow ICCBH attendees with a shared interest in #osteogenesisimperfecta so please come and see us at stand number 6 to speak to one of the team - James Clancy, Hardo Fischer, luigi picaro, Francisco J Rebollo Laserna, Melanie Rüger Rüger Healthcare Consulting GmbH For more information: https://lnkd.in/dFCGuUDf #ICCBH2024 #OI 

For media and investors: Along with our partners Ultragenyx, today Mereo BioPharma announced new data, including fracture and bone mineral density data, from the Phase 2 portion of the Phase 2/3 Orbit study in Osteogenesis Imperfecta. For more information, visit: https://lnkd.in/exVttwcF #OsteogenesisImperfecta #OI

The latest publication from the IMPACT Survey has been published in Orphanet Journal of Rare Diseases and is available on https://lnkd.in/eAs3WVeZ. This paper explores the economic impact of osteogenesis imperfecta (OI) in adults and provides a snapshot of healthcare resource use and costs, as well as the impact of OI on working life. Importantly, it demonstrates the financial strain experienced by the OI community due to various living expenses is a matter of concern for community members. It revealed that adults with OI may face substantial out-of-pocket expenses, irrespective of their sex, age, OI severity or clinical signs, symptoms and events experienced. The IMPACT Survey is the largest ever survey into the impact of OI on people with the condition, their care givers and families. It is a joint initiative between Osteogenesis Imperfecta Federation Europe and its member organizations, the Osteogenesis Imperfecta Foundation and Mereo. It was made possible thanks to the contribution of the OI community. #IMPACTsurveyOI #osteogenesisimperfecta #OI

For investors and media: Mereo is pleased to announce that Denise Scots-Knight will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00am ET / 04:00pm BST. More information is available here https://lnkd.in/dFadmsWp

Mereo will participate at the multi-stakeholder Remedi4All workshop in Bologna, 13 June 2024, to discuss patient-centric approaches to treatment development and availability in #OsteogenesisImperfecta. The OI-dedicated programme for this second Remedi4All event, supported by EURORDIS-Rare Diseases Europe Beacon for Rare Diseases As.It.O.I. - Associazione Italiana Osteogenesi Imperfetta ERN BOND - European Reference Network on Rare Bone Diseases and Osteogenesis Imperfecta Federation Europe, covers developments in research and therapy development; and, importantly, highlights how patient centricity led by the #OI community organisations is contributing to advancing improvements for diagnosis, treatment and care for people with OI at all life-stages; as well as the vital role that collaborative approaches play in securing the best outcomes. https://lnkd.in/dyrJWyz9

For media and investors: Mereo is pleased to announce its financial results for the first quarter ended March 31, 2024, and provide an update on recent corporate highlights. See here for the press release https://lnkd.in/ez7swyp6

Team Mereo in Spain had a busy April, with several important events in the Alpha-1 community’s calendar. Mereo was more than happy to be invited, last April 25th, to support an awareness activity at Hospital Sant Pau, Barcelona, to mark European Alpha-1 Awareness Day. Alpha-1 Europe Alliance asbl use the day to raise awareness of their mission to make diagnosis, care and treatment accessible to all people living with Alpha-1. Mereo was also privileged to be invited to attend the very interesting Alfa 1 España, https://alfa1.org.es/, National Congress in Zamora where we were also celebrating the Alfa 1 España 25th Anniversary. It is always a pleasure to spend time with our communities, listening and learning from them so that we can build strong partnerships. #Europeanalpha1awarenessday #AATD #alpha1antitrypsindeficiency

The Saturn Programme, a Real World Evidence, collaborative, multinational program aimed at supporting the assessment of new medicines in osteogenesis imperfecta, has been presented on 7th May in Rome at the meeting of the Italian ERN BOND - European Reference Network on Rare Bone Diseases. Piloted by the IRCCS Istituto Ortopedico Rizzoli in Bologna, Italy, the Programme will shortly involve other leading OI sites in some European Countries. A collaboration between existing dataset allows identification of common key data variable set. Through the inputs of relevant stakeholders and key research questions, aggregate natural history data output may be reached which allow a better understanding of OI clinical history and help new medicines’ assessment by Regulatory and HTA bodies and payers.  Many burning topics on rare bone diseases have been also discussed in Rome. Among others, the role of ERN Bond within the Italian National Plan for Rare Diseases, the CPMS 2.0 project and the ‘Pronti a Salpare’ project supported by the Rizzoli Institute. Some ongoing trials in rare bone disease have also been presented. The meeting also coincided with the first publication from the SATURN Programme, which can be viewed in the Orphanet Journal of Rare Diseases here https://lnkd.in/dv62u8Ub  #OsteogenesisImperfecta #OI